CYduct Diagnostics, Inc. (CYDX) Stock

About CYduct Diagnostics, Inc.

CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools like dissectors, graspers, scissors, needle holders, fan retractors, cautery devices, and insufflation needles. Furthermore, CYduct supplies illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps, alongside insufflators. For surgical specialties, their portfolio features laparoscopic instruments designed for general surgery, lymphadenectomy, gynecology, and thorascopy. Complementing these are rigid scopes (like laparoscopes, operative scopes, and cystoscopes) with their corresponding accessories, as well as trocar and cannula sets, video carts, and both insulated and non-insulated instrument handles. Uniquely, the company also provides instrumentation tailored for veterinary applications. Established in 1986, CYduct Diagnostics, Inc. is headquartered in Westport, Connecticut. The firm was formerly known as Solos Endoscopy, Inc., before adopting its current name in December 2020.

CYduct Diagnostics, Inc. is headquartered in US.

CYduct Diagnostics, Inc. (CYDX) stock trades at $2.70 with a market capitalization of $14.15M. The stock is valued at a price-to-earnings (P/E) ratio of -40.42, price-to-book of -4.62, price-to-sales of 215.41. Over the past 52 weeks the stock has ranged between $0.20 and $2.90, and currently trades 6.9% below its 52-week high.

On profitability, CYduct Diagnostics, Inc. generates a return on equity (ROE) of 11.90%, return on capital employed of 12.39%, an operating margin of -458.90%, a net profit margin of -532.19%.

Official website: cyductdx.com